|
|
| Oncologie > Etude de marché sectorielle |
| Pipeline Insight: Non-Small Cell Lung Cancer Avastin to lead the market |
|
|
|
|
€ 9 120,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Avril 2006 |
Taille du document : |
234 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
MarketWatch: Cancer
33 pages | Mars 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
32 pages | Juillet 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Octobre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail
71 pages | Janvier 2005 |
IntroductionRoche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003.
This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to |
3 040,00 €
|
| |
| |
Pipeline Insight: Cancer Vaccines and Cell Therapies - Technical Know How Needs Translation Into Clinical and Commercial Rewards
203 pages | Avril 2005 |
IntroductionUnmet need across the cancer market is high, with most therapies conferring low levels of specificity and high toxicity.
Development of cancer vaccines may be the holy grail, with the p |
9 120,00 €
|
| |
| |
Commercial Insight Top 20 Cancer Therapeutics
197 pages | Juillet 2006 |
IntroductionThe Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015.
Cytotoxics currently constitute the majority, due t |
12 160,00 €
|
| |
| |
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp |
955,00 €
|
| |
| |
MarketWatch: Cancer
27 pages | Mai 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Décembre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pipeline Insight: Non-Small Cell Lung Cancer Avastin to lead the market |
|
|
Introduction
Non-small cell lung cancer comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the overall survival of NSCLC patients remains below 12 months.
Scope
Overview of NSCLC and the current treatment options, including profiles and analysis of existing drugs
Insightful analysis of clinical trial data for late-phase drugs in development for NSCLC
Future global sales of key pipeline drugs for NSCLC to 2015, including their clinical/research and commercial attractiveness
Datamonitor's assessment of the clinical and commercial potential of the drugs currently in development for NSCLC
Highlights
Amgen's pantitumumab will prove popular among physicians due to its favorable toxicity profile and EGFR target. With pantitumumab seeking to gain initial approval in the first-line setting, Datamonitor believes the agent will rapidly gain ground on BMS/Merck KgGA's Erbitux, despite the latter's first-to-market advantage.
Over the forecast period to 2015, Datamonitor believes Avastin will be the sole MTT to achieve blockbuster status within the NSCLC market. Avastin's 2015 sales of $1285m are forecast to eclipse those of Tarceva ($737m) and Erbitux ($696m). This is largely attributed to the size of Avastin's target population within the first-line setting.
In attempting to avoid the fate of AstraZeneca's recently withdrawn drug Iressa, developers must allow for adequate maturation of trial data in order to explicitly demonstrate the clinical benefit of novel pipeline agents. The time/cost ratio of clinical development must be regularly reviewed to ensure the commercial success of innovative agents.
Reasons to Purchase
Assess opportunities and risks in the NSCLC market by analyzing the clinical and commercial attractiveness of key agents
Evaluate the potential of your product in the NSCLC cancer market by examining key pipeline drugs' sales forecasts
Determine the commercial impact of new molecular-targeted agents entering the NSCLC market and their effects on the current treatment paradigms
|
|
Introduction
Non-small cell lung cancer comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the overall survival of NSCLC patients remains below 12 months.
Scope
Overview of NSCLC and the current treatment options, including profiles and analysis of existing drugs
Insightful analysis of clinical trial data for late-phase drugs in development for NSCLC
Future global sales of key pipeline drugs for NSCLC to 2015, including their clinical/research and commercial attractiveness
Datamonitor's assessment of the clinical and commercial potential of the drugs currently in development for NSCLC
Highlights
Amgen's pantitumumab will prove popular among physicians due to its favorable toxicity profile and EGFR target. With pantitumumab seeking to gain initial approval in the first-line setting, Datamonitor believes the agent will rapidly gain ground on BMS/Merck KgGA's Erbitux, despite the latter's first-to-market advantage.
Over the forecast period to 2015, Datamonitor believes Avastin will be the sole MTT to achieve blockbuster status within the NSCLC market. Avastin's 2015 sales of $1285m are forecast to eclipse those of Tarceva ($737m) and Erbitux ($696m). This is largely attributed to the size of Avastin's target population within the first-line setting.
In attempting to avoid the fate of AstraZeneca's recently withdrawn drug Iressa, developers must allow for adequate maturation of trial data in order to explicitly demonstrate the clinical benefit of novel pipeline agents. The time/cost ratio of clinical development must be regularly reviewed to ensure the commercial success of innovative agents.
Reasons to Purchase
Assess opportunities and risks in the NSCLC market by analyzing the clinical and commercial attractiveness of key agents
Evaluate the potential of your product in the NSCLC cancer market by examining key pipeline drugs' sales forecasts
Determine the commercial impact of new molecular-targeted agents entering the NSCLC market and their effects on the current treatment paradigms
|
|
|
PPLSEN
|
|
|
|
|
